Report period | 2019 | 2020 | 2021 | 2022 | 2023 | Q2 24 |
---|---|---|---|---|---|---|
End date of the reporting period | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, ₽ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, $ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Enterprise Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Shareholders Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Current liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Noncurrent liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Cash and cash equivalents | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Net debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Assets | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total ordinary shares | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Ordinary share price | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Name | Issue size | Price | Yield |
---|---|---|---|
PROMOMED DM 002P-01 (RUB) | 3,500,000 pcs. | 91.01% | 15.58% |
PROMOMED DM 001P-03 (RUB) | 2,500,000 pcs. | 100% | 9.71% |
PROMOMED DM 001P-01 (RUB) | 1,000,000 pcs. | 100.02% | 0.11% |
PROMOMED DM 001P-02 (RUB) | 977,896 pcs. | 99.96% | 0.19% |
Company name | Promomed |
---|---|
Tags | #biotechnology, #pharmacy, #ipo2024 |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | Moskva, prospekt Mira, dom 13, stroenie 1 |
Mailing address | 129090, g. Moskva, prospekt Mira, dom 13, stroenie 1, etazh 2, pomeschenie 5 |
Website | promomed.ru |
Information disclosure | e-disclosure.ru |